Literature DB >> 30868567

Lessons from exome sequencing in prenatally diagnosed heart defects: A basis for prenatal testing.

Dominik S Westphal1,2, Gloria S Leszinski1, Esther Rieger-Fackeldey3, Elisabeth Graf2, Gregor Weirich4, Thomas Meitinger1,2, Eva Ostermayer5, Renate Oberhoffer6, Matias Wagner1,7.   

Abstract

Congenital heart defects (CHDs) are the most common birth defect with 30%-40% being explained by genetic aberrations. With next generation sequencing becoming widely available, we sought to evaluate the clinical utility of exome sequencing (ES) in prenatally diagnosed CHD. We retrospectively analyzed the diagnostic yield as well as non-conclusive and incidental findings in 30 cases with prenatally diagnosed CHDs using ES, mostly as parent-child trios. A genetic diagnosis was established in 20% (6/30). Non-conclusive results were found in 13% (4/30) and incidental findings in 10% (3/30). There was a phenotypic discrepancy between reported prenatal and postnatal extracardiac findings in 40% (8/20). However, none of these additional, postnatal findings altered the genetic diagnosis. Herein, ES in prenatally diagnosed CHDs results in a comparably high diagnostic yield. There was a significant proportion of incidental findings and variants of unknown significance as well as potentially pathogenic variants in novel disease genes. Such findings can bedevil genetic counseling and decision making for pregnancy termination. Despite the small cohort size, our data serve as a first basis to evaluate the value of prenatal ES in CHD for further studies emerging in the near future.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical genetics; congenital heart disease; exome sequencing; genetics; prenatal

Mesh:

Year:  2019        PMID: 30868567     DOI: 10.1111/cge.13536

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  A systematic literature review of disclosure practices and reported outcomes for medically actionable genomic secondary findings.

Authors:  Julie C Sapp; Flavia M Facio; Diane Cooper; Katie L Lewis; Emily Modlin; Philip van der Wees; Leslie G Biesecker
Journal:  Genet Med       Date:  2021-08-26       Impact factor: 8.864

Review 2.  Application of exome sequencing for prenatal diagnosis: a rapid scoping review.

Authors:  Misty Pratt; Chantelle Garritty; Micere Thuku; Leila Esmaeilisaraji; Candyce Hamel; Taila Hartley; Kathryn Millar; Becky Skidmore; Shelley Dougan; Christine M Armour
Journal:  Genet Med       Date:  2020-08-04       Impact factor: 8.822

3.  Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis.

Authors:  F Mone; R Y Eberhardt; M E Hurles; D J Mcmullan; E R Maher; J Lord; L S Chitty; E Dempsey; T Homfray; J L Giordano; R J Wapner; L Sun; T N Sparks; M E Norton; M D Kilby
Journal:  Ultrasound Obstet Gynecol       Date:  2021-10       Impact factor: 8.678

Review 4.  Prenatal Exome Sequencing: Background, Current Practice and Future Perspectives-A Systematic Review.

Authors:  Daniele Guadagnolo; Gioia Mastromoro; Francesca Di Palma; Antonio Pizzuti; Enrica Marchionni
Journal:  Diagnostics (Basel)       Date:  2021-02-02

5.  Diagnostic yield of exome sequencing for prenatal diagnosis of fetal structural anomalies: A systematic review and meta-analysis.

Authors:  Rhiannon Mellis; Kathryn Oprych; Elizabeth Scotchman; Melissa Hill; Lyn S Chitty
Journal:  Prenat Diagn       Date:  2022-05-07       Impact factor: 3.242

6.  Lessons learnt from prenatal exome sequencing.

Authors:  Natalie J Chandler; Elizabeth Scotchman; Rhiannon Mellis; Vijaya Ramachandran; Rowenna Roberts; Lyn S Chitty
Journal:  Prenat Diagn       Date:  2022-05-07       Impact factor: 3.242

Review 7.  Molecular Approaches in Fetal Malformations, Dynamic Anomalies and Soft Markers: Diagnostic Rates and Challenges-Systematic Review of the Literature and Meta-Analysis.

Authors:  Gioia Mastromoro; Daniele Guadagnolo; Nader Khaleghi Hashemian; Enrica Marchionni; Alice Traversa; Antonio Pizzuti
Journal:  Diagnostics (Basel)       Date:  2022-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.